Articles with "locoregional therapies" as a keyword



Photo from wikipedia

Role of locoregional therapies in the wake of systemic therapy.

Sign Up to like & get
recommendations!
Published in 2020 at "Journal of hepatology"

DOI: 10.1016/j.jhep.2019.09.023

Abstract: Multiple systemic agents have recently been approved in the first- and second-line setting for hepatocellular carcinoma (HCC), increasing the therapeutic options for patients and treating physicians. The randomised controlled trials that led to these approvals… read more here.

Keywords: systemic therapy; systemic agents; role locoregional; locoregional therapies ... See more keywords
Photo from wikipedia

Image-guided percutaneous locoregional therapies for hepatocellular carcinoma.

Sign Up to like & get
recommendations!
Published in 2023 at "Chinese clinical oncology"

DOI: 10.21037/cco-22-119

Abstract: Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the 3rd leading cause of cancer death worldwide. Treatment options include surgical resection, liver transplantation, imageguided percutaneous locoregional options, external beam radiation therapy (EBRT)… read more here.

Keywords: hepatocellular carcinoma; locoregional therapies; percutaneous locoregional; guided percutaneous ... See more keywords
Photo from wikipedia

Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC

Sign Up to like & get
recommendations!
Published in 2021 at "Cancers"

DOI: 10.3390/cancers13225797

Abstract: Simple Summary Interventional radiology image-guided locoregional therapies for the treatment of HCC have demonstrated to be characterized by immunomodulatory effects on the tumoral microenvironment, and, possibly, systemic. Immunotherapy has gained an important role in the… read more here.

Keywords: hcc; immunotherapy; treatment; radiology ... See more keywords
Photo from wikipedia

Locoregional Approaches in Cholangiocarcinoma Treatment

Sign Up to like & get
recommendations!
Published in 2022 at "Cancers"

DOI: 10.3390/cancers14235853

Abstract: Simple Summary Our current ability to treat cholangiocarcinoma is limited. Surgery to remove the tumor is only possible in a small proportion of cases of the disease due to the tumor’s location or spread to… read more here.

Keywords: locoregional approaches; cholangiocarcinoma treatment; locoregional therapies; approaches cholangiocarcinoma ... See more keywords
Photo from wikipedia

Surgical and Oncological Outcomes of Salvage Hepatectomy for Locally Recurrent Hepatocellular Carcinoma after Locoregional Therapy: A Single-Institution Experience

Sign Up to like & get
recommendations!
Published in 2023 at "Cancers"

DOI: 10.3390/cancers15082320

Abstract: Simple Summary For 35 patients with recurrent HCC after primary hepatectomy and 67 patients with recurrent HCC after locoregional therapies, surgical and oncological outcomes were examined. Pathologic review revealed 30 patients with locally recurrent HCC… read more here.

Keywords: locoregional therapies; recurrent hcc; hcc locoregional; locoregional therapy ... See more keywords
Photo from wikipedia

Update on Locoregional Therapies for Cholangiocellular Carcinoma

Sign Up to like & get
recommendations!
Published in 2023 at "Cancers"

DOI: 10.3390/cancers15082368

Abstract: Simple Summary Due to the late onset of symptoms and aggressive growth, cholangiocellular carcinomas (CCA) are associated with poor outcome. In advanced stages, interventional therapies and systemic therapies are particularly used. The combination of locoregional… read more here.

Keywords: combination; cholangiocellular carcinoma; locoregional therapies; therapies cholangiocellular ... See more keywords
Photo from wikipedia

Locoregional therapies and their effects on the tumoral microenvironment of pancreatic ductal adenocarcinoma

Sign Up to like & get
recommendations!
Published in 2022 at "World Journal of Gastroenterology"

DOI: 10.3748/wjg.v28.i13.1288

Abstract: Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second leading cause of death from cancer by 2030. Despite intensive research in the field of therapeutics, the 5-year overall survival is approximately 8%, with only… read more here.

Keywords: therapies effects; ductal adenocarcinoma; locoregional therapies; tumoral microenvironment ... See more keywords